Skip to main content

Advertisement

Log in

Iron and anemia in human biology: a review of mechanisms

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

The biology of iron in relation to anemia is best understood by a review of the iron cycle, since the majority of iron for erythropoiesis is provided by iron recovered from senescent erythrocytes. In iron-deficiency anemia, storage iron declines until iron delivery to the bone marrow is insufficient for erythropoiesis. This can be monitored with clinical indicators, beginning with low plasma ferritin, followed by decreased plasma iron and transferrin saturation, and culminating in red blood cells with low-Hb content. When adequate dietary iron is provided, these markers show return to normal, indicating a response to the dietary supplement. Anemia of inflammation (also known as anemia of chronic disease, or ACD) follows a different course, because in this form of anemia storage iron is often abundant but not available for erythropoiesis. The diagnosis of ACD is more difficult than the diagnosis of iron-deficiency anemia, and often the first identified symptom is the failure to show a response to a dietary iron supplement. Confirmation of ACD is best obtained from elevated markers of inflammation. The treatment of ACD, which typically employs erythropoietin (EPO) supplements and intravenous iron (IV-iron), is empirical and often falls shorts of therapeutic goals. Dialysis patients show a complex pattern of anemia, which results from inadequate EPO production by the kidney, inflammation, changes in nutrition, and blood losses during treatment. EPO and IV-iron are the mainstays of treatment. Patients with heart failure can be anemic, with incidence as high as 50%. The causes are multifactorial; inflammation now appears to be the primary cause of this form of anemia, with contributions from increased plasma volume, effects of drug therapy, and other complications of heart disease. Discerning the mechanisms of anemia for the heart failure patient may aid rational therapy in each case.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig 3
Fig. 4
Fig 5

Similar content being viewed by others

References

  1. Cook JD, Barry WE, Hershko C, Fillet G, Finch CA (1973) Iron kinetics with emphasis on iron overload. Am J Pathol 72:337–343

    PubMed  CAS  Google Scholar 

  2. Bullen JJ, Rogers HJ, Spalding PB, Ward CG (2006) Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol 55:251–258

    PubMed  CAS  Google Scholar 

  3. Roque ME, Sandoval MJ, Aggio MC (2001) Serum erythropoietin and its relation with soluble transferrin receptor in patients with different types of anaemia in a locally defined reference population. Clin Lab Haematol 23:291–295

    PubMed  CAS  Google Scholar 

  4. Erdem A, Erdem M, Arslan M, Yazici G, Eskandari R, Himmetoglu O (2002) The effect of maternal anemia and iron deficiency on fetal erythropoiesis: comparison between serum erythropoietin, hemoglobin and ferritin levels in mothers and newborns. J Matern Fetal Neonatal Med 11:329–332

    PubMed  CAS  Google Scholar 

  5. Artunc F, Risler T (2007) Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant 10:2900–2908

    Google Scholar 

  6. Remy I, Wilson IA, Michnick SW (1999) Erythropoietin receptor activation by a ligand-induced conformation change. Science 283:990–993

    PubMed  CAS  Google Scholar 

  7. Gordeuk VR, Bacon BR, Brittenham GM (1987) Iron overload: causes and consequences. Annu Rev Nutr 7:485–508

    PubMed  CAS  Google Scholar 

  8. Cook JD, Flowers CH, Skikne BS (2003) The quantitative assessment of body iron. Blood 101:3359–3364

    PubMed  CAS  Google Scholar 

  9. Brownlie Tt, Utermohlen V, Hinton PS, Haas JD (2004) Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 79:437–443

    Google Scholar 

  10. Walters GO, Miller FM, Worwood M (1973) Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 26:770–772

    PubMed  CAS  Google Scholar 

  11. Cook JD (1982) Clinical evaluation of iron deficiency. Semin Hematol 19:6–18

    PubMed  CAS  Google Scholar 

  12. Skikne BS, Flowers CH, Cook JD (1990) Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 75:1870–1876

    PubMed  CAS  Google Scholar 

  13. Labbe RF, Dewanji A (2004) Iron assessment tests: transferrin receptor vis-a-vis zinc protoporphyrin. Clin Biochem 37:165–174

    PubMed  CAS  Google Scholar 

  14. Vernet M, Doyen C (2000) Assessment of iron status with a new fully automated assay for transferrin receptor in human serum. Clin Chem Lab Med 38:437–442

    PubMed  CAS  Google Scholar 

  15. Brugnara C, Schiller B, Moran J (2006) Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol 28:303–308

    PubMed  CAS  Google Scholar 

  16. Bakr AF, Sarette G (2006) Measurement of reticulocyte hemoglobin content to diagnose iron deficiency in Saudi children. Eur J Pediatr 165:442–445

    PubMed  CAS  Google Scholar 

  17. Kotisaari S, Romppanen J, Penttila I, Punnonen K (2002) The Advia 120 red blood cells and reticulocyte indices are useful in diagnosis of iron-deficiency anemia. Eur J Haematol 68:150–156

    PubMed  Google Scholar 

  18. Harthoorn-Lasthuizen EJ, Lindemans J, Langenhuijsen MM (1998) Zinc protoporphyrin as screening test in female blood donors. Clin Chem 44:800–804

    PubMed  CAS  Google Scholar 

  19. Lorentz A, Jendrissek A, Eckardt KU, Schipplick M, Osswald PM, Kurtz A (1991) Serial immunoreactive erythropoietin levels in autologous blood donors. Transfusion 31:650–654

    PubMed  CAS  Google Scholar 

  20. Bovy C, Gothot A, Delanaye P, Warling X, Krzesinski JM, Beguin Y (2007) Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrol Dial Transplant 22:1156–1162

    PubMed  CAS  Google Scholar 

  21. Rybo E, Bengtsson C (1985) Sideroblast count and examination of bone marrow reticuloendothelial iron in the diagnosis of iron deficiency. Scand J Haematol Suppl 43:77–85

    PubMed  CAS  Google Scholar 

  22. Murray-Kolb LE, Beard JL (2007) Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 85:778–787

    PubMed  CAS  Google Scholar 

  23. Hallberg L, Hulthen L (2000) Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr 71:1147–1160

    PubMed  CAS  Google Scholar 

  24. Brugnara C, Laufer MR, Friedman AJ, Bridges K, Platt O (1994) Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood 83:3100–3101

    PubMed  CAS  Google Scholar 

  25. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011–1023

    PubMed  CAS  Google Scholar 

  26. Olthof AW, Sijens PE, Kreeftenberg HG, Kappert P, Irwan R, van der Jagt EJ, Oudkerk M (2007) Correlation between serum ferritin levels and liver iron concentration determined by MR imaging: impact of hematologic disease and inflammation. Magn Reson Imaging 25:228–231

    PubMed  CAS  Google Scholar 

  27. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Beguin Y, Invernizzi R, Barosi G, Martini A (1996) Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87:4824–4830

    PubMed  CAS  Google Scholar 

  28. Thomas C, Thomas L (2005) Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 11:14–23

    PubMed  CAS  Google Scholar 

  29. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113:1271–1276

    PubMed  CAS  Google Scholar 

  30. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC (2003) Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 14:1776–1784

    PubMed  CAS  Google Scholar 

  31. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M (2005) Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA 102:1324–1328

    PubMed  CAS  Google Scholar 

  32. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I (2006) Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 108:1381–1387

    PubMed  CAS  Google Scholar 

  33. Kemna EH, Tjalsma H, Podust VN, Swinkels DW (2007) Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 53:620–628

    PubMed  CAS  Google Scholar 

  34. Murphy AT, Witcher DR, Luan P, Wroblewski VJ (2007) Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 110:1048–1054

    PubMed  CAS  Google Scholar 

  35. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454

    PubMed  CAS  Google Scholar 

  36. Thomas C, Kirschbaum A, Boehm D, Thomas L (2006) The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy. Med Oncol 23:23–36

    PubMed  CAS  Google Scholar 

  37. Wians FH Jr, Urban JE, Keffer JH, Kroft SH (2001) Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferrin receptor concentration. Am J Clin Pathol 115:112–118

    PubMed  CAS  Google Scholar 

  38. Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2:619–626

    PubMed  CAS  Google Scholar 

  39. Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806–7810

    PubMed  CAS  Google Scholar 

  40. Canavese C, Bergamo D, Ciccone G, Burdese M, Maddalena E, Barbieri S, Thea A, Fop F (2004) Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol Dial Transplant 19:1564–1570

    PubMed  CAS  Google Scholar 

  41. Peter J, Finkelstein F (2006) The effectiveness of low-dose maintenance i.v. iron therapy: a dialysis facility’s experience. Nephrol Nurs J 33:71–74, 90

    PubMed  Google Scholar 

  42. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH (1992) The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 34:499–508

    PubMed  CAS  Google Scholar 

  43. Gladziwa U, Klotz U, Baumer K, Zollinger R, Mann H, Sieberth HG (1993) Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration. Clin Pharmacokinet 25:145–153

    Article  PubMed  CAS  Google Scholar 

  44. Cahan C, Decker MJ, Arnold JL, Washington LH, Veldhuis JD, Goldwasser E, Strohl KP (1992) Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients. J Appl Physiol 72:2112–2117

    PubMed  CAS  Google Scholar 

  45. Macdougall IC (2006) Recent advances in erythropoietic agents in renal anemia. Semin Nephrol 26:313–318

    PubMed  Google Scholar 

  46. Macdougall IC, Padhi D, Jang G (2007) Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 22(Suppl 4):iv2–iv9

    PubMed  Google Scholar 

  47. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB (2001) Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59:1960–1966

    PubMed  CAS  Google Scholar 

  48. Yeun JY, Levine RA, Mantadilok V, Kaysen GA (2000) C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kid Dis 35:469–476

    PubMed  CAS  Google Scholar 

  49. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A (2004) Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 65:1091–1098

    PubMed  CAS  Google Scholar 

  50. MacFie J (2004) Current status of bacterial translocation as a cause of surgical sepsis. Br Med Bull 71:1–11

    PubMed  Google Scholar 

  51. Kotanko P, Carter M, Levin NW (2006) Intestinal bacterial microflora-a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol Dial Transplant 21:2057–2060

    PubMed  Google Scholar 

  52. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18:975–984

    PubMed  CAS  Google Scholar 

  53. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH (1990) Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557–564

    Article  PubMed  Google Scholar 

  54. Uehlinger DE, Gotch FA, Sheiner LB (1992) A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51:76–89

    Article  PubMed  CAS  Google Scholar 

  55. Means RT Jr (1999) Advances in the anemia of chronic disease. Int J Hematol 70:7–12

    PubMed  Google Scholar 

  56. Handelman GJ (2007) Vitamin C deficiency in dialysis patients-are we perceiving the tip of an iceberg? Nephrol Dial Transplant 22:328–331

    PubMed  Google Scholar 

  57. Deicher R, Ziai F, Bieglmayer C, Schillinger M, Horl WH (2005) Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 16:1811–1818

    PubMed  CAS  Google Scholar 

  58. Handelman GJ (2006) Vitamin C deficiency in dialysis patients—are we perceiving the tip of an iceberg? Nephrol Dial Transplant 22:328–331

    Google Scholar 

  59. Wang S, Geraci G, Kuhlmann MK, Levin NW, Handelman GJ (2007) Chemical reactions of vitamin C with intravenous-iron formulations. Nephrol Dial Transplant 23:120–125

    Google Scholar 

  60. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110:149–154

    PubMed  Google Scholar 

  61. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112:1121–1127

    PubMed  CAS  Google Scholar 

  62. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, Tavazzi L, Latini R, Cohn J (2005) Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 11:91–98

    PubMed  Google Scholar 

  63. Tang YD, Katz SD (2006) Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113:2454–2461

    PubMed  Google Scholar 

  64. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39:1780–1786

    PubMed  Google Scholar 

  65. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, O’Connor CM (2003) Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 92:625–628

    PubMed  Google Scholar 

  66. Paul S, Paul RV (2004) Anemia in heart failure: implications, management, and outcomes. J Cardiovasc Nurs 19:S57–S66

    PubMed  Google Scholar 

  67. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107:223–225

    PubMed  Google Scholar 

  68. Gunnell J, Yeun JY, Depner TA, Kaysen GA (1999) Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33:63–72

    PubMed  CAS  Google Scholar 

  69. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN (2005) C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112:1428–1434

    PubMed  CAS  Google Scholar 

  70. Berry C, Norrie J, Hogg K, Brett M, Stevenson K, McMurray JJ (2006) The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 151:1313–1321

    PubMed  Google Scholar 

  71. Srivastava PM, Thomas MC, Calafiore P, MacIsaac RJ, Jerums G, Burrell LM (2006) Diastolic dysfunction is associated with anaemia in patients with Type II diabetes. Clin Sci (Lond) 110:109–116

    Article  Google Scholar 

  72. Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG (2007) Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 153:1048–1055

    PubMed  CAS  Google Scholar 

  73. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R, Chapman CM (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48:1225–1227

    PubMed  CAS  Google Scholar 

  74. Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657–1665

    PubMed  CAS  Google Scholar 

  75. Ohsugi Y (2007) Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 30:2001–2006

    PubMed  CAS  Google Scholar 

  76. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44:63–67

    PubMed  Google Scholar 

  77. Silva RP, Barbosa PH, Kimura OS, Sobrinho CR, Sousa Neto JD, Silva FA, Silva Junior GB, Mota RM, Daher EF (2007) Prevalance of anemia and its association with cardio-renal syndrome. Int J Cardiol 120:232–236

    PubMed  Google Scholar 

  78. de Silva R, Rigby AS, Witte KK, Nikitin NP, Tin L, Goode K, Bhandari S, Clark AL, Cleland JG (2006) Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 98:391–398

    PubMed  Google Scholar 

  79. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL (2004) Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 147:924–930

    PubMed  Google Scholar 

  80. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26:2232–2237

    PubMed  CAS  Google Scholar 

  81. Androne AS, Hryniewicz K, Hudaihed A, Mancini D, Lamanca J, Katz SD (2004) Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 93:1254–1259

    PubMed  Google Scholar 

  82. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ (2007) Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 28:166–171

    PubMed  CAS  Google Scholar 

  83. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH (2005) Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112:1743–1747

    PubMed  Google Scholar 

  84. Terrovitis JV, Anastasiou-Nana MI, Alexopoulos GP, Tsolakis EJ, Margari ZJ, Drakos SG, Tsagalou EP, Papazoglou P, Efentakis S, Nanas JN (2006) Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril. J Heart Lung Transplant 25:333–338

    PubMed  Google Scholar 

  85. Kotanko P (1996) Intensity of hemodialysis and response to erythropoietin. N Engl J Med 334:1670; author reply 1670–1671

    PubMed  CAS  Google Scholar 

  86. Le Meur Y, Lorgeot V, Comte L, Szelag JC, Aldigier JC, Leroux-Robert C, Praloran V (2001) Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis 38:510–517

    PubMed  CAS  Google Scholar 

  87. ELISA assay for N-acetyl-serylaspartyl-lysyl-proline (Ac-SDKP). Cayman Chemical Company, Ann Arbor, MI

  88. Volpe M, Tritto C, Testa U, Rao MA, Martucci R, Mirante A, Enea I, Russo R, Rubattu S, Condorelli GL, et al (1994) Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 74:468–473

    PubMed  CAS  Google Scholar 

  89. Julian BA, Brantley RR Jr, Barker CV, Stopka T, Gaston RS, Curtis JJ, Lee JY, Prchal JT (1998) Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 9:1104–1108

    PubMed  CAS  Google Scholar 

  90. Freudenthaler SM, Lucht I, Schenk T, Brink M, Gleiter CH (2000) Dose-dependent effect of angiotensin II on human erythropoietin production. Pflugers Arch 439:838–844

    PubMed  CAS  Google Scholar 

  91. Guyatt GH, Patterson C, Ali M, Singer J, Levine M, Turpie I, Meyer R (1990) Diagnosis of iron-deficiency anemia in the elderly. Am J Med 88:205–209

    PubMed  CAS  Google Scholar 

  92. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD (1992) Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med 119:385–390

    PubMed  CAS  Google Scholar 

  93. Annibale B, Capurso G, Delle Fave G (2003) The stomach and iron deficiency anaemia: a forgotten link. Dig Liver Dis 35:288–295

    PubMed  CAS  Google Scholar 

  94. Raja K, Kochhar R, Sethy PK, Dutta U, Bali HK, Varma JS (2004) An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure. Gastrointest Endosc 60:887–893

    PubMed  Google Scholar 

  95. Chodos RB, Wells R Jr, Chaffee WR (1964) A study of ferrokinetics and red cell survival in congestive heart failure. Am J Med 36:553–560

    PubMed  CAS  Google Scholar 

  96. Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, Campagna SM, Nuti R (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152(6): 1096.e9–1096.e15

    Google Scholar 

  97. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P (2007) Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28:2208–2216

    PubMed  Google Scholar 

  98. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K (2007) Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49:753–762

    PubMed  CAS  Google Scholar 

  99. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37:1775–1780

    PubMed  CAS  Google Scholar 

  100. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098

    PubMed  CAS  Google Scholar 

  101. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084

    PubMed  CAS  Google Scholar 

  102. Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388

    PubMed  CAS  Google Scholar 

  103. Danielson BG, Salmonson T, Derendorf H, Geisser P (1996) Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46:615–621

    PubMed  CAS  Google Scholar 

  104. Seligman PA, Dahl NV, Strobos J, Kimko HC, Schleicher RB, Jones M, Ducharme MP (2004) Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy 24:574–583

    PubMed  CAS  Google Scholar 

  105. Van Wyck D, Anderson J, Johnson K (2004) Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19:561–565

    PubMed  Google Scholar 

  106. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J (1999) Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 33:471–482

    PubMed  CAS  Google Scholar 

  107. Mircescu G, Garneata L, Capusa C, Ursea N (2006) Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 21:120–124

    PubMed  CAS  Google Scholar 

  108. Agarwal R (2004) Transferrin saturation with intravenous irons: an in vitro study. Kidney Int 66:1139–1144

    PubMed  CAS  Google Scholar 

  109. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K (2000) Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15:1827–1834

    PubMed  CAS  Google Scholar 

  110. Fishbane S (2003) Safety in iron management. Am J Kidney Dis 41:18–26

    PubMed  Google Scholar 

  111. Agarwal R, Vasavada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279–2289

    PubMed  CAS  Google Scholar 

  112. Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR (2007) Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72:638–642

    PubMed  CAS  Google Scholar 

  113. Attallah N, Osman-Malik Y, Frinak S, Besarab A (2006) Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47:644–654

    PubMed  CAS  Google Scholar 

  114. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC (1999) Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 55:2477–2486

    PubMed  CAS  Google Scholar 

  115. Smith CH, Bidlack WR (1980) Interrelationship of dietary ascorbic acid and iron on the tissue distribution of ascorbic acid, iron and copper in female guinea pigs. J Nutr 110:1398–1408

    PubMed  CAS  Google Scholar 

  116. Handelman GJ (2007) Vitamin C neglect in hemodialysis: sailing between Scylla and Charybdis. Blood Purif 25:58–61

    PubMed  CAS  Google Scholar 

  117. Abuelo JG, Schwartz ST, Reginato AJ (1992) Cutaneous oxalosis after long-term hemodialysis. Arch Intern Med 152:1517–1520

    PubMed  CAS  Google Scholar 

  118. Canavese C, Petrarulo M, Massarenti P, Berutti S, Fenoglio R, Pauletto D, Lanfranco G, Bergamo D, Sandri L, Marangella M (2005) Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 45:540–549

    PubMed  CAS  Google Scholar 

  119. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Eng J Med 339:584–590

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Garry J. Handelman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Handelman, G.J., Levin, N.W. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 13, 393–404 (2008). https://doi.org/10.1007/s10741-008-9086-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-008-9086-x

Keywords

Navigation